Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATL1102 in Nonambulatory Duchenne Muscular Dystrophy
2024-512265-13-00Phase 2Completed
- Sponsor
- Percheron Therapeutics Ltd
- Start
- Jul 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of avicursen in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Percheron Therapeutics Ltd. Primary endpoints: Blinded Phase: Change of Performance of Upper Limb (PUL 2.0) score from baseline to Week 25, OLE Phase (Efficacy): Change of Performance of Upper Limb (PUL 2.0) score from Week 25 to Week 49 and 9 more. Started Jul 2024; status: completed.
02
Drugs
avicursen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2024-512265-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512265-13-00.